Emergency interventions for cardiogenic shock due to decompensated aortic stenosis: a systematic review and meta-analysis.

IF 2.8 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Stephanie Gladys Kühne, Andrea Patrignani, Sebastien Elvinger, Bastian Wein, Eva Harmel, Damyan Penev, Tamer Owais, Evaldas Girdauskas, Philip W Raake, Mauro Chiarito, Dario Bongiovanni
{"title":"Emergency interventions for cardiogenic shock due to decompensated aortic stenosis: a systematic review and meta-analysis.","authors":"Stephanie Gladys Kühne, Andrea Patrignani, Sebastien Elvinger, Bastian Wein, Eva Harmel, Damyan Penev, Tamer Owais, Evaldas Girdauskas, Philip W Raake, Mauro Chiarito, Dario Bongiovanni","doi":"10.1136/openhrt-2024-003110","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment approach remains uncertain.</p><p><strong>Aim: </strong>This study aimed to systematically review and analyse the existing evidence on outcomes of emergency transcatheter aortic valve implantation (eTAVI) and emergency balloon aortic valvuloplasty (eBAV) in CS patients.</p><p><strong>Methods: </strong>A systematic literature review and meta-analysis was performed. The primary endpoint was mortality at 30 days. Secondary endpoints were in-hospital mortality, 1-year mortality, bleeding, major vascular complications, myocardial infarction, stroke, incidence of pacemaker implantation, acute kidney injury and aortic regurgitation.</p><p><strong>Results: </strong>Seventeen studies were included, totalling 2811 patients. The analysis revealed a 30-day mortality pooled estimated rate for eTAVI of 19% (CI 0.17 - 0.20) and for eBAV 39% (CI 0.32 - 0.46). In-hospital mortality pooled estimated rates were 11% for eTAVI (CI 0.06 - 0.18) and for eBAV 40% (CI 0.28 - 0.54). One-year mortality pooled estimated rates for eTAVI were 29% (CI 0.20 - 0.40) and for eBAV 67% (CI 0.58 - 0.74). Pooled estimated rates of any bleeding were 12% for eTAVI (CI 0.06 - 0.20) and 15% for eBAV (CI 0.10 - 0.21). The rate of major vascular complications for eTAVI was 8% (CI 0.07 - 0.10) and 3% for eBAV (CI 0.0 - 0.23).</p><p><strong>Conclusions: </strong>This meta-analysis indicates that mortality in CS due to AS remains high despite emergency interventional treatment. These findings offer critical insights for clinical decision-making optimising patient care in this critically ill population.</p>","PeriodicalId":19505,"journal":{"name":"Open Heart","volume":"12 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751810/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Heart","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/openhrt-2024-003110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment approach remains uncertain.

Aim: This study aimed to systematically review and analyse the existing evidence on outcomes of emergency transcatheter aortic valve implantation (eTAVI) and emergency balloon aortic valvuloplasty (eBAV) in CS patients.

Methods: A systematic literature review and meta-analysis was performed. The primary endpoint was mortality at 30 days. Secondary endpoints were in-hospital mortality, 1-year mortality, bleeding, major vascular complications, myocardial infarction, stroke, incidence of pacemaker implantation, acute kidney injury and aortic regurgitation.

Results: Seventeen studies were included, totalling 2811 patients. The analysis revealed a 30-day mortality pooled estimated rate for eTAVI of 19% (CI 0.17 - 0.20) and for eBAV 39% (CI 0.32 - 0.46). In-hospital mortality pooled estimated rates were 11% for eTAVI (CI 0.06 - 0.18) and for eBAV 40% (CI 0.28 - 0.54). One-year mortality pooled estimated rates for eTAVI were 29% (CI 0.20 - 0.40) and for eBAV 67% (CI 0.58 - 0.74). Pooled estimated rates of any bleeding were 12% for eTAVI (CI 0.06 - 0.20) and 15% for eBAV (CI 0.10 - 0.21). The rate of major vascular complications for eTAVI was 8% (CI 0.07 - 0.10) and 3% for eBAV (CI 0.0 - 0.23).

Conclusions: This meta-analysis indicates that mortality in CS due to AS remains high despite emergency interventional treatment. These findings offer critical insights for clinical decision-making optimising patient care in this critically ill population.

失代偿性主动脉狭窄致心源性休克的紧急干预:系统回顾和荟萃分析。
背景:严重主动脉瓣狭窄(AS)引起的心源性休克(CS)是一种危及生命的疾病,死亡率高。尽管紧急干预措施取得了进展,但最佳治疗方法仍然不确定。目的:本研究旨在系统回顾和分析CS患者急诊经导管主动脉瓣植入术(eTAVI)和急诊球囊主动脉瓣成形术(eBAV)的疗效。方法:进行系统的文献回顾和荟萃分析。主要终点为30天死亡率。次要终点为住院死亡率、1年死亡率、出血、主要血管并发症、心肌梗死、卒中、起搏器植入发生率、急性肾损伤和主动脉反流。结果:纳入17项研究,共2811例患者。分析显示,eTAVI患者的30天总死亡率为19% (CI 0.17 - 0.20), eBAV患者的30天总死亡率为39% (CI 0.32 - 0.46)。eTAVI的住院总死亡率估计为11% (CI 0.06 - 0.18), eBAV的住院总死亡率估计为40% (CI 0.28 - 0.54)。eTAVI的一年总死亡率估计为29% (CI 0.20 - 0.40), eBAV的一年总死亡率估计为67% (CI 0.58 - 0.74)。eTAVI的合并估计出血率为12% (CI 0.06 - 0.20), eBAV的合并估计出血率为15% (CI 0.10 - 0.21)。eTAVI组的主要血管并发症发生率为8% (CI 0.07 - 0.10), eBAV组为3% (CI 0.0 - 0.23)。结论:该荟萃分析表明,尽管进行了紧急介入治疗,但由于AS引起的CS死亡率仍然很高。这些发现为临床决策提供了重要的见解,以优化这一危重患者的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Open Heart
Open Heart CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
4.60
自引率
3.70%
发文量
145
审稿时长
20 weeks
期刊介绍: Open Heart is an online-only, open access cardiology journal that aims to be “open” in many ways: open access (free access for all readers), open peer review (unblinded peer review) and open data (data sharing is encouraged). The goal is to ensure maximum transparency and maximum impact on research progress and patient care. The journal is dedicated to publishing high quality, peer reviewed medical research in all disciplines and therapeutic areas of cardiovascular medicine. Research is published across all study phases and designs, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Opinionated discussions on controversial topics are welcomed. Open Heart aims to operate a fast submission and review process with continuous publication online, to ensure timely, up-to-date research is available worldwide. The journal adheres to a rigorous and transparent peer review process, and all articles go through a statistical assessment to ensure robustness of the analyses. Open Heart is an official journal of the British Cardiovascular Society.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信